Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 7:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 33,144 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Scleroderma, Systemic
Interventions: Thalidomide, Placebo thalidomide; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Wound Infection, Abscess, Systemic Inflammation, Cellulitis
Interventions: Single-Dose IV Oritavancin Diphosphate, IV Vancomycin; Drug
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,019 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: La Mesa, California

Conditions: Overweight or Obesity
Interventions: AMG 133, Placebo, Acetaminophen; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Moderate to Severe Genital Psoriasis
Interventions: Tildrakizumab 100 mg, Placebo; Drug
Lead sponsor: Sun Pharmaceutical Industries Limited; Industry
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 36
States / cities: Anaheim, California • Encinitas, California • Encino, California + 30 more

Conditions: HIV Infections
Interventions: ALVAC-HIV (vCP1452), LIPO-5; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 174 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 11
States / cities: Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 6 more

Conditions: Pulmonary Hypertension Associated With HFpEF
Interventions: TNX-103, Placebo; Drug
Lead sponsor: Tenax Therapeutics, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 45
States / cities: Alexander City, Alabama • Tucson, Arizona • Sacramento, California + 40 more

Conditions: Healthy
Interventions: melatonin, Placebo; Dietary Supplement · Other
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 35 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Norman, Oklahoma

Conditions: Coronary Atherosclerosis
Interventions: Rimonabant (SR141716), Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 839 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: End Stage Renal Disease, Chronic Kidney Disease, Sleep Disorder
Interventions: Melatonin; Drug
Lead sponsor: Southeast Renal Research Institute; Other
Eligibility: 18 Years to 85 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Chattanooga, Tennessee

Conditions: Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Minimal Change Disease
Interventions: Abatacept, Normal Saline, D5W; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 6 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 27
States / cities: Birmingham, Alabama • Torrance, California • Aurora, Colorado + 19 more

Conditions: Tick Bites, Tick-borne Illness
Interventions: Permethrin Impregnated Uniforms; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 159 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Hallux Valgus, Hallux Rigidus
Interventions: magnesium-cannabidiolic acid cream, Placebo cream; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cancer Survivor, Stage I Breast Cancer AJCC v7, Stage I Colon Cancer AJCC v6 and v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage II Colon Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIA Colon Cancer AJCC v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIB Colon Cancer AJCC v7, Stage IIC Colon Cancer AJCC v7, Stage III Breast Cancer AJCC v7, Stage III Colon Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIA Colon Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIB Colon Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IIIC Colon Cancer AJCC v7
Interventions: American Ginseng, Laboratory Biomarker Analysis, Placebo, Questionnaire Administration; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Herpes Zoster, Inflammatory Disease, Rheumatoid Arthritis
Interventions: Varicella Zoster Vaccine, Placebo Injection; Biological · Other
Lead sponsor: Kevin Winthrop; Other
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 5
States / cities: Boise, Idaho • Eagan, Minnesota • Clovis, New Mexico + 2 more

Conditions: Healthy
Interventions: Canagliflozin (JNJ-28431754), Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 3
Interventions: Placebo, Sotagliflozin; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 787 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 51
States / cities: Birmingham, Alabama • Guntersville, Alabama • Phoenix, Arizona + 42 more

Conditions: Healthy
Interventions: SPY001-001, Placebo; Drug · Other
Lead sponsor: Spyre Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Cypress, California

Conditions: Overactive Bladder
Interventions: Solabegron modified release tablets, low dose, Solabegron modified release tablets, high dose, Matching Placebo; Drug
Lead sponsor: Velicept Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 1,413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 77
States / cities: Birmingham, Alabama • Guntersville, Alabama • Saraland, Alabama + 61 more

Conditions: Subarachnoid Hemorrhage, Acute Kidney Injury
Interventions: Sodium chloride /sodium acetate (16.4%), Sodium chloride (23.4%), PlasmaLyte; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hand Osteoarthritis, Osteoarthritis
Interventions: Non-invasive circulation gloves, Fabric gloves; Device
Lead sponsor: Altoona Center for Clinical Research; Network
Eligibility: 40 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Duncansville, Pennsylvania

Conditions: ADHD, Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder With Hyperactivity, Mental Disorders Diagnosed in Childhood, Attention Deficit and Disruptive Behavior Disorders
Interventions: Methylphenidate ER, Cyproheptadine; Drug
Lead sponsor: Douglas Sears; Individual
Eligibility: 6 Years to 12 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Van Nuys, California

Conditions: Opioid-related Disorders
Interventions: Heroin, Naloxone, Low Bup Dose, High Bup Dose, Low Bup/Nal Dose, High Bup/Nal Dose, Placebo (PCB); Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 21 Years to 45 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Anastrozole, AZD0530 (saracatinib), Placebo; Drug
Lead sponsor: Joyce Marie Slingerland, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 2
States / cities: Palo Alto, California • Miami, Florida

Conditions: Overweight, Obesity
Interventions: Semaglutide, Placebo semaglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 7
States / cities: Birmingham, Alabama • Costa Mesa, California • Honolulu, Hawaii + 4 more

Search by objective public record fields.

Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis

Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection

The Effect of AMG 133 on Gastric Emptying

A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.

A Study of LIPO-5 and ALVAC-HIV (vCP1452) as Possible HIV Vaccines

LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2

The Effects of Acute Melatonin Supplementation on Cardiovascular Responses to Sympathetic Activation

STRADIVARIUS (Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant - the Intravascular Ultrasound Study)

Different Doses of Oral Melatonin Supplements in Chronic Kidney Disease (CKD)-Associated Sleep Disorders

Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)

Tick-borne Illness and Clothing Study

Effect of Topical CBD Cream for Degenerative Hallux Disorders

Ginseng in Decreasing Cancer-Related Fatigue After Treatment in Cancer Survivors

The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept

Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese Volunteers

Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control

A Study of SPY001-001 in Healthy Volunteers

A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)

A Low ChloridE hyperTonic Solution for Brain Edema

Effect of Semiconductor Embedded Therapeutic Gloves for Hand Osteoarthritis

A Study of Combination Therapy in Children With ADHD

Abuse Liability of Suboxone Versus Subutex

A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer

Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range